First-in-human prospective trial of sonobiopsy in high-grade glioma patients using neuronavigation-guided focused ultrasound.
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
16 Sep 2023
16 Sep 2023
Historique:
received:
20
03
2023
accepted:
05
09
2023
medline:
17
9
2023
pubmed:
17
9
2023
entrez:
16
9
2023
Statut:
epublish
Résumé
Sonobiopsy is an emerging technology that combines focused ultrasound (FUS) with microbubbles to enrich circulating brain disease-specific biomarkers for noninvasive molecular diagnosis of brain diseases. Here, we report the first-in-human prospective trial of sonobiopsy in high-grade glioma patients to evaluate its feasibility and safety in enriching plasma circulating tumor biomarkers. A nimble FUS device integrated with a clinical neuronavigation system was used to perform sonobiopsy following an established clinical workflow for neuronavigation. Analysis of blood samples collected before and after FUS sonication showed that sonobiopsy enriched plasma circulating tumor DNA (ctDNA), including a maximum increase of 1.6-fold for the mononucleosome cell-free DNA (cfDNA) fragments (120-280 bp), 1.9-fold for the patient-specific tumor variant ctDNA level, and 5.6-fold for the TERT mutation ctDNA level. Histological analysis of surgically resected tumors confirmed the safety of the procedure. Transcriptome analysis of sonicated and nonsonicated tumor tissues found that FUS sonication modulated cell physical structure-related genes. Only 2 out of 17,982 total detected genes related to the immune pathways were upregulated. These feasibility and safety data support the continued investigation of sonobiopsy for noninvasive molecular diagnosis of brain diseases.
Identifiants
pubmed: 37717084
doi: 10.1038/s41698-023-00448-y
pii: 10.1038/s41698-023-00448-y
pmc: PMC10505140
doi:
Types de publication
Journal Article
Langues
eng
Pagination
92Subventions
Organisme : NIBIB NIH HHS
ID : R01 EB030102
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS128461
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB027223
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA276174
Pays : United States
Organisme : NIMH NIH HHS
ID : UG3 MH126861
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH116981
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2023. Nature Publishing Group UK.
Références
Neuro Oncol. 2021 Oct 1;23(10):1789-1797
pubmed: 33693781
Phys Rev Lett. 2011 Jan 21;106(3):034301
pubmed: 21405276
Brain Res. 2008 Jan 10;1188:198-206
pubmed: 18031717
Nat Cancer. 2020 Mar;1(3):276-290
pubmed: 35122035
PLoS One. 2016 Jul 14;11(7):e0159094
pubmed: 27416070
Neurology. 2012 Oct 16;79(16):1693-8
pubmed: 23035067
Mol Ther Nucleic Acids. 2013 Jul 23;2:e109
pubmed: 23881452
Oncotarget. 2016 Feb 23;7(8):8712-25
pubmed: 26556853
Sci Adv. 2021 Feb 5;7(6):
pubmed: 33547073
Sci Rep. 2018 Apr 26;8(1):6553
pubmed: 29700310
Theranostics. 2022 Jan 1;12(1):362-378
pubmed: 34987650
Nat Biotechnol. 2016 May;34(5):547-555
pubmed: 27018799
Front Oncol. 2020 Sep 10;10:1663
pubmed: 33014832
Cancers (Basel). 2019 Jul 05;11(7):
pubmed: 31284524
Cancers (Basel). 2021 Nov 14;13(22):
pubmed: 34830853
Theranostics. 2020 Mar 15;10(10):4544-4556
pubmed: 32292514
Cancer Discov. 2017 Dec;7(12):1394-1403
pubmed: 28899864
J Neurooncol. 2023 May;162(3):461-469
pubmed: 36717507
Sci Transl Med. 2021 Oct 13;13(615):eabj4011
pubmed: 34644145
JAMA Oncol. 2019 Aug 01;5(8):1124-1131
pubmed: 31070691
J Neurosurg. 2020 Jan 03;134(2):475-483
pubmed: 31899873
Cancer Discov. 2016 May;6(5):479-91
pubmed: 26969689
PLoS One. 2020 Jun 3;15(6):e0234182
pubmed: 32492056
Nat Commun. 2019 Sep 26;10(1):4373
pubmed: 31558719
J Thorac Oncol. 2018 Sep;13(9):1248-1268
pubmed: 29885479
Adv Drug Deliv Rev. 2022 Dec;191:114583
pubmed: 36272635
Ann Transl Med. 2017 Feb;5(3):46
pubmed: 28251125
Sci Rep. 2021 Jul 22;11(1):15043
pubmed: 34294761
Curr Neurol Neurosci Rep. 2016 Mar;16(3):25
pubmed: 26838352
Expert Rev Mol Diagn. 2017 Oct;17(10):943-947
pubmed: 28875730
J Neurosurg. 2022 Nov 04;139(1):275-283
pubmed: 36334289
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Proc Natl Acad Sci U S A. 2017 Jan 3;114(1):E75-E84
pubmed: 27994152
Fluids Barriers CNS. 2022 Dec 23;19(1):103
pubmed: 36564820
Expert Rev Med Devices. 2021 May;18(5):429-437
pubmed: 33945369
Nat Commun. 2018 Jul 25;9(1):2336
pubmed: 30046032
Theranostics. 2017 Sep 15;7(16):3989-4000
pubmed: 29109793
Radiology. 2021 Sep;300(3):681-689
pubmed: 34227880
Radiology. 2001 Sep;220(3):640-6
pubmed: 11526261
Int J Mol Sci. 2021 Jun 29;22(13):
pubmed: 34210107
EMBO Mol Med. 2021 Aug 9;13(8):e12881
pubmed: 34291583
IEEE Trans Biomed Eng. 2023 May;70(5):1528-1538
pubmed: 36374883
Radiology. 2023 Apr;307(2):e220869
pubmed: 36719290
Nat Commun. 2021 Feb 3;12(1):779
pubmed: 33536430
Sci Rep. 2019 Jan 23;9(1):321
pubmed: 30674905
Br J Cancer. 2021 Jan;124(2):345-358
pubmed: 32968207
Clin Cancer Res. 2021 Jan 1;27(1):169-178
pubmed: 33051308
Sci Rep. 2020 May 4;10(1):7449
pubmed: 32366915